GLP-1 Side Effects: What Clinical Trials Found and How to Manage Them
Key Takeaways
- Nausea is the most common side effect, affecting 31-44% of clinical trial participants depending on the medication and dose. Most cases are mild to moderate and decrease after the first few months.
- The FDA cleared GLP-1 medications of suicide and self-harm risk in January 2026 after reviewing 91 trials and nearly 108,000 patients
- Practical management strategies (slower dose titration, dietary changes, timing adjustments) can significantly reduce side effect severity
- Serious side effects like pancreatitis and gallbladder issues occur in a small percentage of patients but require awareness
If you are starting a GLP-1 medication or thinking about it, you have probably seen side effect lists that range from reassuring to alarming. The problem is that most of those lists lack context. Knowing that nausea is "common" is different from knowing that 44% of people on semaglutide 2.4 mg experienced it in clinical trials, that the median duration was 8 days, and that it typically peaks during dose escalation and decreases afterward.
This guide provides the actual numbers from clinical trials, explains what to expect at each stage, and covers practical strategies for managing side effects. The data comes from published studies and FDA prescribing information.
Programs with Clinical Support
Common Side Effects by the Numbers
Gastrointestinal side effects are the most frequently reported issues with GLP-1 medications. The rates differ between semaglutide and tirzepatide, and between different doses of the same medication.
GI Side Effect Rates from Clinical Trials
| Side Effect | Semaglutide 2.4 mg | Tirzepatide 15 mg | Placebo |
|---|---|---|---|
| Nausea | 44% | 31% | 9-16% |
| Vomiting | 25% | 12% | 2-6% |
| Diarrhea | 30% | 23% | 7-16% |
| Constipation | 24% | 12% | 6-11% |
Semaglutide data: STEP 1-3 pooled analysis and Wegovy FDA label. Tirzepatide data: SURMOUNT-1 GI tolerability analysis and Zepbound FDA label.
Important Context
These numbers need a few qualifiers. First, the placebo groups also reported significant rates of GI symptoms (9-16% for nausea). Some of this is the nocebo effect: when you expect side effects, you notice symptoms you might otherwise ignore.
Second, these are rates over the full trial period, not what you experience on any given day. In the STEP trials, nausea peaked around week 20 (during dose escalation) and decreased after reaching the maintenance dose. The median duration of a nausea episode was 8 days. Vomiting episodes lasted a median of 2 days. Constipation lasted longer (median 47 days in the semaglutide group).
Third, severity matters. The STEP pooled analysis found that most GI events were mild to moderate. GI side effects led to dose reduction or temporary pause in 12.5% of semaglutide participants. Complete discontinuation due to GI events was 5.6% for semaglutide and 2.7% for tirzepatide in the head-to-head trial.
Other Common Side Effects
Beyond the GI effects, clinical trials reported:
- Headache affected 13-14% of participants, compared to 10% on placebo. Usually transient and concentrated in early treatment.
- Fatigue was reported by 9-11% (vs 5-7% on placebo). Often improves as the body adjusts to the medication and as caloric intake stabilizes.
- Injection site reactions tend to be more common with tirzepatide than semaglutide, though generally mild and localized.
- Dizziness occurred in 5-7% of participants. Staying hydrated and eating regular small meals helps.
How to Manage Side Effects
Clinical guidelines from the WHO (December 2025) and a multidisciplinary expert consensus published in the Journal of Clinical Medicine offer specific strategies.
Dose Titration: The Most Important Strategy
Both medications start at a low dose and increase gradually. If GI side effects occur at a particular dose, guidelines recommend staying at that dose for an additional 2-4 weeks before increasing. Do not escalate while symptoms persist. Your provider can also set a maintenance dose below the recommended maximum if the lower dose is effective and better tolerated.
If anti-nausea medication is still needed after one month at a given dose, that is a signal to consider reducing the dose rather than adding more medication on top.
Dietary Changes That Help
| Symptom | What Helps | What to Avoid |
|---|---|---|
| Nausea | Eat smaller meals (5-6 per day). Ginger tea. Crackers, apples, or mint. Eat slowly. | Large meals. Sweet, spicy, or fried foods. Eating past the point of fullness. |
| Vomiting | Prioritize hydration. BRAT diet (bananas, rice, applesauce, toast) until it passes. | Carbonated beverages. Lying flat immediately after eating. |
| Diarrhea | Water with lemon and a teaspoon of bicarbonate. Temporarily reduce fiber. Consider probiotics. | High-fiber foods initially (reintroduce gradually). Isotonic sports drinks. |
| Constipation | Increase water intake (64+ oz daily). Dietary fiber (once acute symptoms resolve). Physical activity. | Low fluid intake. Sedentary behavior. |
Timing and Hydration
Separate fluid intake from meals. Drink 30-60 minutes before or after eating rather than during. This helps with both nausea and the feeling of excessive fullness that some people experience early in treatment.
Staying hydrated is especially important with vomiting or diarrhea. Aim for at least 64 ounces of water daily.
When to Consider Switching
If side effects remain intolerable despite slower dose escalation and dietary modifications, options include switching to a different GLP-1 medication (semaglutide to tirzepatide or vice versa) or changing the route of administration. The oral semaglutide pill, approved in December 2025, may be better tolerated than the injection for some patients, though this has not been directly studied in the weight management dose.
Serious Side Effects: What the Data Shows
Headlines about GLP-1 risks can be alarming. The clinical trial data provides more context than most news coverage.
Pancreatitis
Both medications list acute pancreatitis as a warning in their prescribing information. The actual incidence in clinical trials was low: 3 cases out of 1,306 semaglutide participants in STEP 1, with no cases in the placebo group. A meta-analysis of randomized controlled trials found no statistically significant increase in pancreatitis risk (OR 0.7, 95% CI 0.5-1.2).
A larger meta-analysis of 62 studies with over 66,000 patients did find a modest increase in relative risk (RR 1.44), but this lost statistical significance when researchers controlled for background medications. Interestingly, a TriNetX database study found that semaglutide and tirzepatide were associated with reduced risk of recurrent pancreatitis in people who already had a history of the condition.
Gallbladder Disease
This is the most clearly established serious risk. A JAMA Internal Medicine meta-analysis of 76 randomized controlled trials found a 37% higher relative risk of gallbladder disease and a 70% higher rate of gallbladder removal (cholecystectomy) in GLP-1 users compared to controls.
Context matters here: rapid weight loss of any kind increases gallstone risk. This is well documented after bariatric surgery and aggressive dietary weight loss too. Higher GLP-1 doses and longer treatment duration correlate with higher gallstone risk, which aligns with the weight-loss-mediated mechanism.
In the STEP trials, gallbladder disorders occurred in approximately 1.6-2.6% of semaglutide participants compared to 0.7-1.2% on placebo. Small numbers overall, but worth being aware of, particularly if you have a history of gallbladder issues.
Thyroid Cancer Boxed Warning
Both Wegovy® and Zepbound® carry a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma). This is based on findings in rodent studies where lifetime exposure to GLP-1 medications caused dose-dependent thyroid tumors.
The human evidence tells a different story. A systematic review of 10 clinical trials involving over 14,500 participants found less than 1% developed any thyroid cancer, with no evidence of a causal link. Long-term cardiovascular outcome trials showed stable calcitonin levels (the marker for MTC) over 3+ years of treatment. The European Medicines Agency reviewed the evidence and found "no evidence to suggest a causal relationship."
The boxed warning remains because the rodent signal warrants continued monitoring, and both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
The Suicide Question: Answered
Starting in 2023, reports to the FDA's adverse event reporting system raised concerns about suicidal thoughts and behavior in patients taking GLP-1 medications. This triggered a comprehensive review that the FDA concluded on January 13, 2026.
The FDA evaluated three independent sources of evidence:
FDA Suicide/Self-Harm Review
| Evidence Source | Scope | Finding |
|---|---|---|
| Clinical trial meta-analysis | 91 trials, 107,910 patients | No increased risk of suicidal ideation, behavior, anxiety, depression, or other psychiatric events |
| FDA Sentinel System | 2.2 million patients (real-world data) | No increased risk of intentional self-harm vs matched controls |
| Published literature | Observational and pooled studies | Totality of evidence does not support a causal relationship |
Based on these findings, the FDA requested manufacturers remove the suicidal ideation and behavior information from the labeling of semaglutide (Wegovy®), tirzepatide (Zepbound®), and liraglutide (Saxenda®).
This is significant because the concern about mental health side effects was a reason some patients delayed or avoided starting treatment. The evidence from the largest review conducted to date (nearly 108,000 patients across 91 trials) found no signal.
If you are experiencing depression, anxiety, or suicidal thoughts for any reason, contact the 988 Suicide and Crisis Lifeline (call or text 988) or talk to your healthcare provider.
Body Composition Changes
One concern that gets attention is the loss of lean body mass (muscle) during GLP-1 treatment. Any form of significant weight loss results in some muscle loss, not just medication-assisted weight loss. The question is how much.
What the DEXA Scan Data Shows
In the STEP 1 body composition substudy, which used DEXA scans (the gold standard for measuring body composition), participants on semaglutide 2.4 mg lost an average of 6.92 kg of lean mass while losing 15.2 kg total. That puts lean mass at about 45.5% of total weight lost, which is higher than the typical 20-30% benchmark seen with dietary weight loss.
However, there is an important nuance: the proportion of lean mass relative to total body mass actually improved by 3 percentage points. In other words, even though absolute muscle mass decreased, body composition (the ratio of lean to fat) got better.
The tirzepatide SURMOUNT-1 DEXA substudy showed lean mass comprising about 34.3% of total weight lost, which is closer to the normal benchmark. A broader meta-analysis of 22 trials estimated lean mass loss at approximately 25% of total weight lost across the GLP-1 class.
What You Can Do About It
A 2025 case series found that patients who combined GLP-1 treatment with resistance training and adequate protein intake preserved or even increased lean tissue. This aligns with decades of research showing that resistance exercise is the most effective countermeasure against lean mass loss during any form of weight reduction.
Practical recommendations: aim for at least 2-3 resistance training sessions per week and 0.7-1.0 grams of protein per pound of body weight daily. These targets come from general sports nutrition guidelines and are not specific to GLP-1 patients, but the principle applies.
"Ozempic Face" and Changes in Appearance
"Ozempic face" refers to facial volume loss and skin laxity that can occur with significant weight loss. A 2025 systematic review in plastic surgery literature documented these changes. The same appearance changes occur after bariatric surgery or large dietary weight loss. They are a consequence of losing facial fat, not a unique drug side effect.
The effect is more noticeable in people who lose larger amounts of weight and in older patients with less skin elasticity. Slower weight loss and maintaining adequate nutrition may reduce the severity, though this has not been directly studied.
When to Contact Your Provider
Most side effects are manageable and expected. Some symptoms warrant a call to your healthcare provider.
| Contact Your Provider If... | Why |
|---|---|
| Severe abdominal pain that does not go away | Could indicate pancreatitis. Stop the medication and seek evaluation. |
| Persistent vomiting or inability to keep fluids down | Risk of dehydration. May need dose adjustment or temporary hold. |
| Signs of gallbladder problems | Right upper abdominal pain after eating, especially fatty food. Nausea with fever. |
| Vision changes | Rare, but rapid improvement in blood sugar can temporarily affect vision in diabetic patients. |
| Signs of allergic reaction | Rash, itching, swelling, difficulty breathing. Seek immediate care. |
| Lump or swelling in your neck | Related to thyroid warning. Your provider will evaluate. |
Having a provider who offers ongoing clinical support matters when managing side effects. Some programs include messaging or video check-ins where you can ask questions between scheduled appointments. Others are limited to the initial prescription. When comparing providers, ask about the support structure for managing side effects during treatment.
The Bottom Line
GLP-1 medications cause GI side effects in a significant number of patients. For most people, these symptoms are mild to moderate and fade after the first few months as the body adjusts to the maintenance dose.
The serious risks (pancreatitis, gallbladder disease) are uncommon but worth understanding. And the suicide concern has been resolved by the FDA's comprehensive review of nearly 108,000 patients.
A good provider helps you manage side effects through slower dose escalation and dietary guidance rather than just prescribing and moving on. Ongoing clinical support makes a measurable difference in how well people tolerate treatment.
Compare Provider Support
Clinical support during treatment varies significantly between providers. See what each program includes.
Compare ProvidersHow We Evaluate Weight Loss Programs
We look at medical oversight quality, ongoing support during treatment, medication options, pricing transparency, and insurance compatibility. For side effect management specifically, we note whether programs offer messaging support, video check-ins, and clinician access between scheduled appointments.
Featured Programs with Clinician Support
These programs include licensed clinician consultations and ongoing support. Compare what each offers.
Sources
- Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of semaglutide 2.4 mg: STEP 1-3 pooled analysis. Diabetes Obes Metab. 2022.
- Rubino D, et al. Gastrointestinal tolerability of tirzepatide: SURMOUNT-1 analysis. Diabetes Obes Metab. 2025.
- FDA. Wegovy prescribing information. 2024.
- FDA. Zepbound prescribing information. 2024.
- FDA. Update on evaluation of suicidal thoughts with GLP-1 RAs. January 13, 2026.
- Rausch J, et al. Expert consensus on GI adverse event management with GLP-1 RAs. J Clin Med. 2023.
- WHO. Global guideline on GLP-1 medicines in treating obesity. December 2025.
- He L, et al. GLP-1 RAs and risk of gallbladder and biliary diseases. JAMA Intern Med. 2022.
- Alkhezi OS, et al. Thyroid cancer risk with semaglutide: systematic review. 2024.
- Wilding JPH, et al. Body composition changes with semaglutide: STEP 1 substudy. Diabetes Obes Metab. 2021.
- Neeland IJ, et al. Lean body mass changes with GLP-1 RAs: meta-analysis. Diabetes Obes Metab. 2024.